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Abstract: Stroke is a significant cause of long-term disability. Currently, once damage from a stroke is established little 
can be done to recover lost function. Cell transplantation emerged as possible alternative therapy, on the basis of animal 
studies showing that cells transplanted into the brain not only survive but also lead to functional improvement in different 
neurodegenerative diseases. Stem cells have been tested in stroke patients as a possible treatment option. While initially 
stem cells seemed to work by a “cell replacement” mechanism, it is emerging that cell therapy works mostly by providing 
trophic support to the injured tissue and brain, fostering both neurogenesis and angiogenesis. This review summarizes 
clinical studies on stem cell transplantation in stroke patients to evaluate the safety, feasibility of administration and toler-
ability of this experimental treatment.  
At present there is little evidence to assess the applicability of this treatment in stroke patients and well designed clinical 
trials are necessary to evaluate safety and toxicity as well as optimal cell type, route and time of delivery.  
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INTRODUCTION 
 Stroke is the third leading cause of death and disability 
among the adult population in developed countries. Despite 
immediate medical attention and some interventions during 
the acute phase of stroke such as thrombolytic agents [1], 
many patients still have persistent deficits. In addition to 
therapies addressed to improve cerebral blood flow, there has 
been increasing emphasis on neuroprotective strategies, but 
at the present time no cytoprotective agents have been 
proven to be effective [2-4]. Once the damage from a stroke 
event has maximized, little can be done to restore premorbid 
function. Thus, there is a compelling need to develop treat-
ments aimed at reducing neurological deficits. In experimen-
tal stroke the injured brain shows features that seem recapitu-
late the CNS development as suggested by the observed in-
duction of an array of genes and proteins last seen in the em-
bryonic and developing brain [5]. This observation suggests 
that injured brain is primed for potentiation of neurorestora-
tive processes. There are multiple strategies to promote these 
restorative processes, including cell-based and pharma-
cologic therapies [6-14]. Data from animal models support 
the safety and effectiveness of stem cell transplantation to 
enhance neurological recovery from severe ischaemic stroke. 
Cells transplanted to the brain not only survive, but also lead 
to functional improvement in different neurodegenerative 
diseases models [15-17].  
 On this observation stem cell transplantation could repre-
sent a potential therapeutic strategy for some neurological  
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disorders including cerebrovascular diseases. Cell-based 
therapies, that are under investigation so far, include a vari-
ety of cells such as bone marrow mesenchymal, cord blood, 
fetal and embryonic cells [18, 19]. Transplanted cells are 
believed to give some benefits not only directly by cell re-
placement in damaged tissues, but also through trophic, neu-
roprotective and immunomodulatory effects. It is supposed 
that grafted cells, through secretion of trophic factors, pre-
serve existing host cells and connections, enhance synaptic 
activity and provide a bridge for host axonal regeneration 
[20]. It is believed that they also amplify endogenous proc-
esses of brain plasticity, including neurogenesis and angio-
genesis that may contribute to neurological function im-
provement after stroke. This review summarizes clinical 
studies on stem cell transplantation in stroke patients to 
evaluate safety, feasibility of administration and tolerability 
of this experimental therapy. 
CLINICAL TRIALS FOR STROKE PATIENTS 
 Different stem cells sources such as embryonic stem cells 
(ESCs), neuroepithelial or teratocarcinoma cell lines, neural 
stem cells (NSCs) from the embryonic or adult brain or stem 
cells from other tissues (e.g. bone marrow) are under investi-
gation in stroke transplantation, by using different methods 
for their isolation and culture.  
 Following the promising results in animal models, few 
clinical trials have been implemented.  
 To date, 7 small clinical trials in humans evaluated the 
safety and the effect of different stem cells on stroke out-
come (Table 1) [21-27]. 
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 In 1998, the US Food and Drug Administration (FDA), 
on the basis of data from experimental studies, approved a 
small phase I open-label trial in which neuroteratocarcinoma 
(NT2N) cells were transplanted in stroke patients [21]. In 
animal models, immortalized cell line NT2 (derived from a 
human testicular germ cell tumor) shows an exclusive com-
mitment to a neural lineage when exposed to retinoic acid 
(RA) [28, 29]. Grafted NT2N cells into adult mice brain 
have been shown in several studies to elaborate processes 
within 3 weeks reaching terminal differentiation by 6-8 
weeks and to survive up to 14 months without reverting to a 
neoplastic state [30]. They express surface markers and cy-
toskeletal proteins characteristics of mature neurons [21]. 
Transplanted cells also release neurotransmitters and elabo-
rate typical neuronal proteins. Intrastriatal transplantation 1 
month after middle cerebral artery (MCA) occlusion, fol-
lowed by immunosuppression with cyclosporin, led to a sig-
nificant improvement at passive avoidance test (a test of 
learning behavior retention time) and elevated body swing 
test compared to ischemic animals that received rat fetal 
cerebellar grafts, growth medium alone, or cyclosporin alone 
[30]. The ready constant availability of cryopreserved pure 
neurons has made the NT2N cells an attractive implant 
source.  
Table 1. Clinical Studies of Stem-Cell Transplantation  
Study  
Reference 
Type of 
Study 
Sample Type of Stem 
Cells 
Mode of Delivery Type of Stroke Mean Time 
Since Onset of 
Stroke 
Results 
Kondziolka et 
al., 2000 
Phase I trial 12 NT2N cells* Stereotactic implan-
tation 
Ischemic involving 
basal ganglia (8 cases) 
or basal ganglia and 
cerebral cortex (4 cases) 
27 months No cell-related adverse 
effects 5 years after cell 
transplantation 
Kondziolka et 
al., 2005 
Phase II 
randomized 
trial 
18 NT2N cells* Stereotactic implan-
tation 
Ischemic (9 cases) or 
hemorrhagic (9 cases, 
involving basal ganglia 
but no motor cortex  
3.5 years A single seizure the day 
after the surgery and a 
subdural hematoma 1 
month after transplanta-
tion. No evidence of a 
significant benefit in 
motor function but it 
indicate the safety and the 
feasibility of neuron 
transplantation  
Savitz et al., 
2005 
Phase I trial 5 Fetal Porcine 
cells 
Stereotactic implan-
tation 
Ischemic involving the 
striatum 
4.9 years The study was termined 
by the FDA§ after 2 pa-
tients developed adverse 
events 
Bang et al., 
2005 
Phase I e II 
randomized 
trial 
30  
(5 
cases) 
MSC+ Intravenous injec-
tion 
Ischemic in middle 
cerebral artery territory 
46.6 days No cell-related adverse 
effects 1 year after cell 
transplantation 
Rabinovich et 
al. 2005 
Case series 10 Human Fetal 
cells 
Subarachnoidal 
injection 
Ischemic (7 cases) or 
hemorrhagic (3 cases) 
involving the middle 
cerebral artery territory 
12.1 months Some patients developed 
fever and meningism 48 
hours after transplantation 
Man et al. 
2006 
Case series 10 HUCBSC Superficial vein of 
back of the hand 
Ischemic (6 cases) or 
hemorrhagic (4 cases) 
23.5 months No side effects (immuno-
suppressive treatment was 
not used) 
Yang et al. 
2005 
Case series 26 Embryonic 
neural stem cells 
Microinvasive intra-
lesion injection in 3 
acute patients with 
haematoma. 
Subarachnoid injec-
tion in the remaining 
patients 
Ischemic (15 cases) or 
hemorrhagic (11 cases) 
3 acute hemor-
rhagic strokes 
and 23 chronic 
(4.2 years) 
Transient fever in 4 pa-
tients 
*Immortalized NT2 cell line derived from a human teratocarcinoma. 
§FDA= Federal Drug Administration. 
+mesenchymal stem cells. 
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 The 12 recruited patients experienced a basal ganglia 
stroke 6 months to 4.5 years before implantation and re-
ceived, on the base of preclinical data, doses from 2 to 6 mil-
lion cells. An immunosuppressive treatment with cyclosporin 
was performed for 8 weeks. Five years after surgery there 
were no adverse events related to the implant. One patient 
had a single seizure 6 months after surgery which was 
thought to be related to incident stroke and not to surgery, 
implantation or prior cyclosporin use. Subsequent medical 
problems have been attributed to cardiovascular risk factors 
and advancing age. Autopsy on 1 patient, who died for myo-
cardial infarction 27 months after the surgical procedure, 
revealed a population of immunoreactive grafted cells with-
out signs of inflammation, infection or neoplasia, suggesting 
that the grafts can safely survive, without continued immu-
nosuppression [31].  
 Moreover, positron emission tomography (PET) scanning 
at 6 months showed high uptake of F-18 fluorodeoxyglucose 
at transplant site in 6 patients, suggesting cellular activity 
that could be due to graft survival, but also attributable to 
inflammatory response [32].  
 Although this trial was not designed to evaluate efficacy, 
6 patients presented an improvement in the European Stroke 
Scale (ESS) scores at 24 weeks and these data, in some pa-
tients, correlated with increased PET metabolic activity [21].  
 In the following years Kondziolka et al. [22] presented a 
phase II randomized open-label trial to test safety, feasibility 
and effectiveness of NT2N cell transplantation for stroke. 
Eighteen patients, aged 18-75 years, with stable deficit 1 to 6 
years after ischemic or hemorrhagic basal ganglia stroke, 
were randomized to receive either 5 or 10 million implanted 
cells (7 patients per group) or to serve as non-surgical con-
trol group (4 patients). Patients received cyclosporin A for 1 
week before and 6 months after surgery. All recruited sub-
jects underwent to a stroke rehabilitation program. One pa-
tient experienced a single seizure the day after the surgery 
and another one developed a subdural hematoma evacuated 1 
month after transplantation. No cell-related adverse serologi-
cal and imaging events were observed by serial evaluations. 
The primary outcome was ESS motor score at 6 months. 
Secondary end points included Fugl-Meyer Stroke Assess-
ment, Action Reach Arm Test, Stroke Impact Scale and re-
sults of comprehensive cognitive testing. In transplanted 
patients the ESS motor score did not significantly differ from 
controls, instead some secondary outcome measures such as 
the Stroke Impact Scale, Everyday Memory scores and Ac-
tion Reach Arm Test were significantly improved in the 
treatment arm of the study [22]. Four transplanted subjects 
who had stroke in non dominant hemisphere showed marked 
improvement on the Rey Complex figure test, reflecting that 
cell transplants can restore some cognitive functions such as 
planning and organization abilities [33]. This study demon-
strated the feasibility of neuronal cells implantation proce-
dures in human. 
 Savitz and colleagues [23] stereotactically injected fetal 
porcine cells into 5 patients 25 to 52 years old who experi-
enced basal ganglia stroke between 1.5 and 10 years before. 
Ten deposits of 100 000 cells/mm
3
 were made for each tra-
jectory to total 10
6
x10
6
 cells per needle tract. The study was 
stopped by the FDA because 2 patients developed adverse 
events. One patient had a worsening of a motor deficit wors-
ening weeks after intervention due to cerebral infarct de-
tected by MRI and the second one developed seizures 1 
week after transplantation. In this last patient the cerebral 
MRI showed a ring enhancing lesion subjacent to the site of 
the first hole where no implantation occurred. At 4 years of 
clinical follow-up 2 patients showed functional improvement 
but none of patients showed improvement on the modified 
Rankin scale. 
 Bang and colleagues [24] presented a randomized con-
trolled phase I/II clinical trial of mesenchymal stem cell 
(MSCs) transplantation in massive cortical infarct of the 
middle cerebral artery (MCA) territory. The aim of the study 
was to verify feasibility, efficacy and safety of cell replace-
ment therapy using cultured autologous MSCs, evaluating 
post implantation clinical outcome and neuroradiological 
features. Thirty patients (30-75 years old), within 7 days of 
stroke, were randomly allocated to receive intravenous infu-
sion of autologous MSCs (5 patients) or no intervention (25 
patients). No cell-related adverse effects were reported. At 1 
year follow-up, Barthel index and modified Rankin score 
showed a non-significant trend toward improved scores in 
patients treated with MSCs. Also, changes in NIHSS scores 
were not substantial.  
 The authors conclude that MSCs transplantation is safe 
and feasible, even if they underline the need of implementa-
tion of double-blind large cohort studies to confirm their 
promising results. 
 Rabinovich et al. [25] injected human fetal cells into the 
subarachnoid space of 10 patients aged 35-56 years between 
4 and 24 months after their ischemic or haemorrhagic stroke 
of MCA territory. Humal fetal cells were obtained from hu-
man fetuses after spontaneous or prostaglandin-induced 
abortion. Some patients developed fever and meningism 
within 48 h after transplantation. The control group was cho-
sen retrospectively and the outcome measures were not 
clearly described. These shortcomings preclude any conclu-
sion about efficacy. 
 Man et al. in 2006 [26] published 1 study on 10 Chinese 
patients with stroke sequelae (6 ischemic and 4 hemorrhagic) 
who were treated, after a time ranging from 3 months-7 years 
(mean 23.5 months), with 6 portions (1x10
8
 cells/portion) of 
human umbilical cord blood stem cells (HUCBSC) i.v. The 
study was designed to evaluate the improvement of both 
neurological function and daily living activity through a pre- 
transplantation and a 3 months follow-up evaluation using 
neurological function deficiency (NFD) test, Fugl-Meyer 
Assessment (FMA) score, ADL and Barthel Index. No side 
effects were reported and, despite immunosuppressive treat-
ment were not used during the whole procedure, no immu-
nological or allergic reaction was observed. Since FMA and 
BI were significantly higher at 3 months follow-up, the 
authors conclude that this procedure is easy feasible and ef-
fective. However, the follow-up is short and a neuroimaging 
evaluation after transplantation to observe infarct lesion evo-
lution was not performed. Moreover, a control group was not 
planned. 
 Yang et al. in 2005 [27] investigated intrathecal injection 
of embryonic neural stem cells (ENSCs) in 26 patients (15 
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ischemic and 11 haemorrhagic); 3 patients had acute hemor-
rhagic stroke whereas 23 patients suffered from ischemic or 
haemorrhagic stroke within 3 months-30 years (mean 4.2 
years). In the 3 acute patients with haematoma volume be-
tween 35 and 40 mL a microinvasive intracerebral haema-
toma puncture was performed and a suspension of ENSCs 
was conducted to the lesion by a drainage tube. In the other 
patients cells were intrathecally administered into the suba-
rachnoidal space and flowed to the cerebral surface through 
CSF circulation. Patient outcome was evaluated both through 
instrumental data (EEG, CT; MRI) and clinical assessment, 
but the time of outcome evaluation is not clearly indicated. 
No side effects were registered except for transient fever in 4 
patients. Twenty-three patients improved at ESS and at Bar-
tel Index. However, it has to be considered that patients also 
underwent to physical, occupational and speech therapies 
and the study lacks of a control group. 
 We found other 6 published Chinese studies evaluating 
stem cells transplantation in patients with different cere-
brovascular disorders [34-39]. Since only English language 
abstracts of these studies are available, we did not include 
them in this review. 
 Currently, 3 clinical ongoing studies are still recruiting 
stroke patients for stem cell therapy. 
 The first study, conducted in UK, is a randomized, pla-
cebo-controlled, dose-escalation pilot study aimed at deter-
mining safety, tolerability and effects on impairment, disabil-
ity and dependency of an autologous CD34+ subset of bone 
marrow stem cell infusion into the MCA in patients who 
have suffered from acute total anterior circulation syndrome 
(TACS) [40]. The second is a phase I trial sponsored by a 
UK biotechnology company, evaluating the safety of trans-
formed human neural line cells transplantation in patients 
with stroke [41].  
 The third study is conducted in Brazil. The purpose of 
this study is to evaluate the safety and feasibility of intra-
arterial injection of autologous bone marrow mononuclear 
cells in patients in the acute and sub-acute phase (<7 days 
after symptoms onset) of ischemic cerebral infarct in the 
MCA territory [42]. The results of this study are not avail-
able and the study is ongoing. 
DISCUSSION 
 Despite some initial promising results, the potential suc-
cess of transplantation in stroke, in comparison to neurode-
generative diseases, is influenced by some critical issues 
including anatomy, localization and size of infarct area, time 
of transplantation, vascular supplies, route and site of im-
plantation and patient selection [18, 43]. 
 First, neuronal damage induced by stroke is not selective 
but involves different neuronal and also glial cell popula-
tions. Moreover, stroke, also affecting white matter in addi-
tion to gray matter, can disrupt different anatomical path-
ways. Therefore, it would be necessary that cell sources do 
not have restricted fates and can differentiate into appropri-
ate cell types in relation to ectopic site other than they should 
be able to produce functional connections. 
 The second point is the lesion site. Most experimental 
studies used stroke model with damage in the striatum where 
cells were directly delivered. Since only few authors investi-
gated cell therapy for cortex infarcts [44-46], it is still un-
clear whether transplanted cells can restore cortical damage.  
 Third, the appropriate transplantation time after stroke is 
still unknown, considering that the brain environment 
changes over time after stroke. Excitotoxic neurotransmit-
ters, free radicals and proinflammatory mediators are re-
leased in acute phase and cell death by apoptosis may last up 
to several weeks [47, 48]. The activated inflammatory re-
sponse that lead to microglial reaction together with apop-
totic processes in the acute phase act as negative factors for 
the growth and survival of transplanted cells [49, 50]. Oth-
erwise, in the acute phase, cytokines and neurotrophic fac-
tors such as G-CSF [51] are also released and it has been 
observed that they modulate neuronal growth, angiogenesis, 
cell proliferation, differentiation and migration from subven-
tricular zone [52]. In delayed transplantation the scar tissue 
could negatively affect cells implantation.  
 Another important point is the vascular support of im-
plant site. Increased vascularisation, spontaneously induced 
in the penumbra area during neurological recovery, has been 
described to correlate with longer survival in stroke patients 
[53] and could represent a potential target for cell therapy 
[54-57]. Transplanted stem cells have been demonstrated to 
secrete and promote the release of endogenous factors such 
as Stromal Derived Factor-1 (SDF-1), Brain Derived Neu-
rotrophic Factor (BDNF), Fibroblast Growth Factor (FGF), 
Vascular Endothelial Growth Factor (VEGF) and Granolo-
cyte-Monocyte Colony-Stimulating Factor (GM-CSF), 
which increase angiogenesis.  
 Finally, the route of cell administration is another key 
point of stem cells transplantation. Different ways of deliv-
ery (intracerebral, intraventricular or intravenous) have been 
used in animal models and in stroke patients [58, 59]. De-
spite it has been observed that cells induce a similar recovery 
independently from the way of administration, intracerebral 
transplantation seems to be the best route. In the acute phase 
it could be better to inject cells into the penumbral area, 
where viable environment is present [60]. Alternatively, 
transplant delivery could be made distant from the infarct 
area, for instance in the contralateral side, that takes the ad-
vantage of healthy and well vascularized environment [61]. 
In fact some authors demonstrated that both intact and dam-
aged hemisphere after stroke attracts grafted stem cells [62]. 
Intravenous administration, although less invasive, raises the 
question if cells target other organs than the lesion site. 
 The result of these small initial clinical studies included 
in this paper indicates that stem cell therapy may be safe and 
technically feasible in stroke patients. However, data are 
only preliminary and insufficient to assess efficacy. The re-
sults of available studies are compatible with the notion that 
stem cells transplantation significantly improves some func-
tional outcomes (e.g. ESS, BI, Fugl-Meyer Assessment of 
motor recovery, cognitive functions, etc) in stroke patients. 
However, studies are not comparable for heterogeneity in 
term of patient populations, type of cells, timing of injection 
and mode of delivery. Moreover, the significance of these 
results is unclear considering small simple size of studies and 
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lack double-blinded controls. Thus, the best experimental 
condition cannot be defined. Side effects were observed in 3 
of 7 studies presented above [21, 23, 25] and safety is a prin-
cipal concern. Epilepsy, risk of bleeding or thrombosis at the 
site of injection and risk of malignant transformation are still 
limiting factors. Therefore, we cannot draw a definitive con-
clusion on the safety of stem cells transplantation. In the 
Kondziolka et al. [22] and Bang et al. [24] studies there was 
no evidence of teratoma transformation but the length of 
follow-up was only one year and longer-term follow-up are 
required to rule out the tumorigenic potential of implanted 
cells [21, 24].  
 Several key questions need to be answered by higher 
quality randomised clinical trials. Since statins have been 
demonstrated to improve neurological functional outcome by 
promoting angiogenesis, neurogenesis and synaptic plasticity 
in experimental studies [63-65], it could be interesting to 
investigate whether the concomitant administration of stat-
ins, whose tolerability and safety have been widely proven in 
humans [66], could influence outcome of stroke patients 
after stem cell transplantation.  
 However, although animal models differ significantly 
from their human counterparts, better investigation of the 
effects of stem cell treatment on stroke within well-designed 
preclinical studies could improve the quality of clinical trials.  
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